Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis
Oncology · 29.05.2026 · 1-6
DOI: 10.1159/000552768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, online erschienen am 29.05.2026. Verfasst von Gakushi Komura und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Introduction
Real-world evidence is limited for patients with unresectable hepatocellular carcinoma (HCC) who are ineligible for locoregional therapy (LRT) at initial diagnosis. We examined diagnostic pathways and outcomes of first-line atezolizumab plus bevacizumab (Atz+Bev), with a focus on de novo LRT-ineligible HCC.
Methods
We retrospectively analyzed 107 systemic therapy-naïve patients with unresectable HCC who received Atz+Bev as first-line systemic therapy. Patients were categorized into LRT-naïve (n = 55) and LRT-experienced (n = 52) groups. Diagnostic pathways, baseline characteristics, and treatment outcomes were evaluated.
Results
Among LRT-naïve patients, 34.5% presented with HCC-related symptoms, whereas the majority were diagnosed incidentally during outpatient care for metabolic comorbidities, often triggered by mild liver enzyme abnormalities. In this group, clinically meaningful disease control was observed despite a high intrahepatic tumor burden at presentation, with an objective response rate of 41.8% and a disease control rate of 87.3%. Median progression-free survival was 11.7 months. Clinical outcomes were generally comparable between the LRT-naïve and LRT-experienced groups.
Conclusion
Atz+Bev provides clinically meaningful disease control in patients presenting with de novo LRT-ineligible unresectable HCC. The frequent incidental mode of diagnosis highlights opportunities to strengthen risk stratification and surveillance in high-risk metabolic liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, Japan.
- Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, Japan, teiji.kuzuya@fujita-hu.ac.jp.
- Department of Gastroenterology and Hepatology, Fujita Health University Bantane Hospital, Nagoya, Japan.
- Department of Gastroenterology, Fujita Health University Okazaki Medical Center, Okazaki, Japan.
Zitieren
APA
Komura, G., Kuzuya, T., Muto, H., Tachi, Y., Kobayashi, M., Sugiyama, H., Ariga, M., Morisaki, S., Nakano, T., Tanaka, H., Nakaoka, K., Ohno, E., Funasaka, K., Nagasaka, M., Miyahara, R., & Hirooka, Y. (2026). Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis. Oncology, 1-6. https://doi.org/10.1159/000552768
Vancouver
Komura G, Kuzuya T, Muto H, Tachi Y, Kobayashi M, Sugiyama H, et al. Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis. Oncology. 2026:1-6. doi:10.1159/000552768
BibTeX
@article{Komura2026,
author = {Komura, Gakushi and Kuzuya, Teiji and Muto, Hisanori and Tachi, Yoshihiko and Kobayashi, Mariko and Sugiyama, Hijiri and Ariga, Mizuki and Morisaki, Sayaka and Nakano, Takuji and Tanaka, Hiroyuki and Nakaoka, Kazunori and Ohno, Eizaburo and Funasaka, Kohei and Nagasaka, Mitsuo and Miyahara, Ryoji and Hirooka, Yoshiki},
title = {Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis},
journal = {Oncology},
year = {2026},
pages = {1--6},
doi = {10.1159/000552768}
}
EUVIMED